IQVIA Research & Development Solutions’ Post

With many research programs and activities that impact the #RareDiseases community, NCATS has established itself as a leader in rare diseases research at The National Institutes of Health. We collaborate with patients, advocates and researchers to get more treatments for all people more quickly. Explore how NCATS is addressing the significant and often unmet needs of those affected by rare diseases: https://go.nih.gov/njCpKfm

The Global Alliance for Chronic Diseases (GACD) have developed eight top tips for researchers to help them engage with and influence policymakers. These eight tips contain in-depth insights as well as practical examples from GACD projects! Find out more here: https://lnkd.in/eA8nyjaR #cervicalcancer #publichealth #healthpolicy

Summary: The study by Laporta et al. aims to estimate the prevalence of chronic Chagas disease (CCD) in Brazilian municipalities from 2010–2022. Statistical modeling identified key predictors, with an estimated 3.25% prevalence in 3,778 municipalities, totaling ~3.7 million cases in Brazil. The study underscores the challenge of vertical transmission, urging inclusion in the national program for elimination. via Pan American Journal of Public Health https://ift.tt/8GrbaPx #healthpolicy, #healthsystems, #policy

Long COVID is still an issue. More than 36 million people across the European Region may have developed long COVID over the pandemic years. With the EuCARE cohort of PASC patients, our international team of scientists and researchers is investigating the role of the different viral variants in response to treatment interventions and in disease progression, including long-term outcome, and to identify predictors of patients at higher risk. #LongCovidAwarenessDay #longcovid #covid19 World Health Organization European Commission

Today is #RareDiseaseDay! 🦄 At Synergy we are proud to contribute to the research into rare diseases. Those battling rare diseases are often overlooked or misunderstood, but there are thousands of rare diseases that impact many in the UK and millions of people globally. It is so important we strive for a deeper understanding and to overcome the challenges faced by patients, their families and the healthcare system. Last year we were delighted that the research Synergy conducted for BioIndustry Association (BIA) was published as part of their report "Rare insights: Examining the social values of treating rare diseases", which looked at public opinion of how rare diseases should be evaluated and funded within the NHS. You can read the report here: https://lnkd.in/eGsueKZQ #healthcare #marketresearch #healthcaremarket

Explore the latest insights on Liver Diseases from Mount Sinai. From new treatments to addressing disparities, this report covers it all. Check it out: https://bit.ly/49dxFgG #Healthcare #Research #LiverDiseases

Exciting News! The World Health Organization and partners are advancing efforts to address non-communicable diseases! Strategic partnerships, implementation research, and global collaboration are key to achieving impactful outcomes. This commentary highlights the key insights and recommendations for NCD research set to transform global health. Read here: https://lnkd.in/ekh-V8hT

Causal inference in public health is about identifying and understanding the causal relationships between various factors and health outcomes in populations. It involves using statistical methods and research designs to determine the impact of specific interventions or exposures on public health outcomes. From epidemiological viewpoint, it is essential to boost community healthcare and diseases prevention. #DAG structure learning plays systematically essential role in identifying important risk factors.

On March 1, 2024, the #FDA will host a virtual public meeting for patients and health care professionals. They will discuss the following topics amongst others: • The legal framework for approving studies and medical products at FDA • What FDA does during review processes to approve medical products • Decentralized clinical trials and digital health technologies • Where to find important information and documents related to clinical trials • Legal and ethical requirements for consent forms in clinical trials • What FDA does during review processes to approve medical products The timing is not so ideal for our Australian colleagues, unless you're a night owl. But, it could be worthwhile staying up for. Check it out if you're interested in or thinking of doing #clinicaltrials in the U.S. #decentralizedtrials #clinicalresearch #drsuenguyen

We are excited to announce the topics for our future funding calls, focusing on implementation science to address the global burden of non-communicable diseases. Following expert consultations, we have developed three key funding call topics for 2025–2027 which will address critical areas including transforming health systems, leveraging sectors beyond health, and empowering the next generation. Read more about these funding call topics: https://lnkd.in/erbnH2BN